de Bitter, Tessa J. J. http://orcid.org/0000-0002-8669-3834
de Reuver, Philip R.
de Savornin Lohman, Elise A. J.
Kroeze, Leonie I.
Vink-Börger, Marianne E.
van Vliet, Shannon
Simmer, Femke
von Rhein, Daniel
Jansen, Erik A. M.
Verheij, Joanne
van Herpen, Carla M. L.
Nagtegaal, Iris D.
Ligtenberg, Marjolijn J. L. http://orcid.org/0000-0003-1290-1474
van der Post, Rachel S. http://orcid.org/0000-0002-7531-9599
Funding for this research was provided by:
Foundation ADP Radboud Oncologie Fonds Foundation Mi Corazon
Article History
Received: 17 May 2022
Accepted: 17 October 2022
First Online: 5 November 2022
Competing interests
: Dr. Rachel S. van der Post participated in advisory board meetings of Bristol Myers Squibb (2021) and HER2 testing in gastric cancer (2021). Prof. dr. Marjolijn J.L. Ligtenberg participates in advisory boards of Astra Zeneca, Roche, Bayer, Merck Sharp & Dohme B.V., Jansen-Cilag B.V., Bristol-Myers Squibb and Lilly. Prof. dr. Carla M.L. van Herpen participates in advisory boards of Bayer, Bristol-Myers Squibb, Ipsen, MSD and Regeneron and received research grants, outside the submitted work, from Astra-Zeneca, Bristol-Myers Squibb, MSD, Merck, Ipsen, Novartis, and Sanofi. All other authors declare no competing interests.